# A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant

> **NCT01903928** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 9 (actual)

## Conditions studied

- Allogeneic Hematopoietic Cell Transplant

## Interventions

- **BIOLOGICAL:** ASP0113

## Key facts

- **NCT ID:** NCT01903928
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-20
- **Primary completion:** 2015-01-19
- **Final completion:** 2015-01-19
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903928, "A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01903928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*